The nonprofit Physicians Committee for Responsible Medicine, which promotes the use of human-relevant test methods to replace ...

The US Food and Drug Administration (FDA) has approved bevacizumab-nwgd (Jobevne, Biocon Biologics Ltd), a biosimilar to bevacizumab (Avastin, Genentech), for intravenous use across multiple cancer ...

The U.S. Food and Drug Administration has approved Jobevne (bevacizumab-nwgd), a biosimilar to Avastin (bevacizumab) for ...

Cruelty Free International welcomes major shift towards humane, modern approaches to drug development and testing ...

The FDA has approved bevacizumab-nwgd, a biosimilar to bevacizumab, for intravenous use across multiple cancer types.

Sandoz sues Amgen in U.S. court over Enbrel patents, alleging efforts to block biosimilar Erelzi and delay competition in the ...

To help bring down sky-high drug prices, President Donald Trump signed an executive order pushing for faster biosimilar ...

Chime Biologics, a leading global CDMO that enables its partners' success in biologics, is pleased to announce a strategic ...

Affirming that analytical characterization is often sufficient for biosimilar approval, minimizing unnecessary clinical ...

Biocon Biologics has received the Food and Drug Administration ... "The U.S. FDA approval of Jovevne (bevacizumab-nwgd) is a significant milestone—our seventh biosimilar approved in the ...

BIOCON), today announced that the U.S. Food and Drug Administration (U.S. FDA) has approved Jobevne™ (bevacizumab-nwgd), a biosimilar Bevacizumab for intravenous use. JOBEVNE, a recombinant ...

In 2023, bevacizumab sales in the U.S. were around $2.0 billion. Biocon Biologics serves over 5 million patients each year ...